Trial Profile
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Smoldering multiple myeloma
- Focus Pharmacodynamics
- 07 Jul 2016 Status changed from completed to discontinued as lab staff that was required left the institution, therefore accrual closed prematurely.
- 20 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jul 2014 Planned End Date changed from 1 Dec 2013 to 1 Jul 2015 as reported by ClinicalTrials.gov